Sign in
TerminatedPhase 1

Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis

Key facts

Who runs it
St. Petersburg State Pavlov Medical University
Where
Russia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
20 people enrolled
Started
1 Jun 2019
Ended
29 Nov 2023
Type of study
Interventional
Treatments tested
  • allogeneic fecal microbiota
Record updated
6 December 2023
Why it stopped
the bio-samples are corrupted for technical reasons

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Diagnosis: Multiple sclerosis (Relapsing-Remitting, Secondary-Progressive, Primary-Progressive)
  • AutoHSCT
  • Signed informed consent
  • No second tumors
  • No severe concurrent illness
  • 1.0-6.5 points by EDSS
  • Disease duration less than 20 years
  • Disease progression on 1 and/or 2 line therapy (1 point EDSS 1.0-6.0 and 0,5 point EDSS 6.0-6.5)

Who cannot take part

  • Uncontrolled bacterial or fungal infection at the time of enrollment
  • Somatic or psychiatric disorder making the patient unable to sign informed consent
  • Moderate or severe cardiac dysfunction, left ventricular ejection fraction <50%
  • Severe organ dysfunction: AST or ALT >5 upper normal limits, bilirubin >1.5 upper normal limits, creatinine >2 upper normal limits
  • Creatinine clearance < 60 mL/min
  • Moderate or severe decrease in pulmonary function, FEV1 <70% or DLCO<70% of predicted
  • Respiratory distress >grade I
  • Requirement for vasopressor support at the time of enrollment
  • Karnofsky index <30%
  • Pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The hypothesis of the study is that according to modern data, the pathogenesis of multiple sclerosis is inextricably linked to the patient's microbiota. Therefore, transplantation of a normal fecal microbiota (FMT) can improve the outcome of autologous hematopoietic stem cell transplantation (autoHSCT) by increasing the disease-free period and disease progression suspension for at least 5 years after transplantation, which meets the NEDA (No Evidence of Disease Activity) criteria, satisfying the current trends of clinical neurology.

The group in the trial

  • AutoHSCT + FMTTreatment being tested

    AutoHSCT with reduced intensity condition regimen (RIC). FMT starting D+60 up to D+120 via po capsules: 30 capsules with fecal transplant divided in two consecutive days (more accurate capsules amount is according to patients body weight)

    Treatment: allogeneic fecal microbiota

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Allogeneic Fecal Microbiota Transplantation as a Consolidation Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Sclerosis
Record updated
6 December 2023